​

Esperion Therapeutics Ownership | Who Owns Esperion Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Esperion Therapeutics Ownership Summary

Esperion Therapeutics is owned by 49.10% institutional investors, 0.61% insiders, and 50.29% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 8.92% of ESPR shares. BB Biotech AG Ord is the top mutual fund, with 5.05% of its assets in Esperion Therapeutics shares.

ESPR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEsperion Therapeutics49.10%0.61%50.29%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustrySpecialty & Generic Drug Manufacturers Stocks20.82%11.62%67.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de17.68M8.92%$65.42M
Blackrock13.98M8.26%$31.04M
Vanguard group14.95M7.54%$55.30M
Two seas capital lp11.90M6.01%$44.04M
Wasatch advisors lp9.45M4.77%$34.95M
Penderfund capital management6.68M3.39%$17.69M
Geode capital management5.74M2.90%$21.23M
State street4.48M2.28%$11.87M
Meditor group3.79M2.24%$8.42M
Aigh capital management4.00M2.02%$14.80M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Meditor group3.79M15.57%$8.42M
Aigh capital management4.00M3.58%$14.80M
Penderfund capital management6.68M2.98%$17.69M
Two seas capital lp11.90M0.91%$44.04M
Caitong asset management30.46K0.31%$112.71K
Summit wealth group340.61K0.29%$1.26M
Integral health asset management1.50M0.27%$3.98M
Diametric capital, lp236.15K0.23%$625.78K
Wasatch advisors lp9.45M0.21%$34.95M
Logos global management lp750.00K0.18%$1.99M

Top Buyers

HolderShares% AssetsChange
Blackrock13.98M0.00%11.14M
Vanguard group14.95M0.00%2.85M
Blackrock funding, inc. /de17.68M0.00%2.85M
Wasatch advisors lp9.45M0.21%2.38M
Two seas capital lp11.90M0.91%2.15M

Top Sellers

HolderShares% AssetsChange
Orbimed advisors---13.71M
Bellevue group---9.69M
Great point partners---5.79M
Bank of america corp /de/1.16M0.00%-3.38M
Indaba capital management---3.00M

New Positions

HolderShares% AssetsChangeValue
Integral health asset management1.50M0.27%1.50M$3.98M
Logos global management lp750.00K0.18%750.00K$1.99M
Walleye capital319.19K0.00%319.19K$845.86K
Voleon capital management lp207.88K0.01%207.88K$550.88K
Polen capital management116.29K0.00%116.29K$430.28K

Sold Out

HolderChange
Assetmark-8.00
Td waterhouse canada-59.00
Rothschild investment-100.00
Geowealth management-102.00
Cornerstone planning group-123.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025137-31.50%97,287,936-9.92%491.63%75-29.25%21-43.24%
Sep 30, 2025119-26.54%54,298,682-41.97%271.22%59-13.24%23-41.03%
Jun 30, 2025168-11.58%98,172,969-13.34%491.49%67-17.28%44-21.43%
Mar 31, 2025190-7.77%113,479,021-9.95%571.38%82-8.89%5621.74%
Dec 31, 202486-56.78%36,541,743-71.74%180.43%38-51.28%15-65.91%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord9.94M5.05%-
Pender Corporate Bond F6.36M3.18%359.98K
Vanguard Total Stock Mkt Idx Inv7.53M3.15%255.43K
Vanguard US Total Market Shares ETF6.18M3.12%-
iShares Russell 2000 ETF5.66M2.37%4.36M
Wasatch Small Cap Growth Investor4.35M2.21%-43.99K
Wasatch Ultra Growth4.42M1.85%-16.74K
Pender Corporate Bond A4.06M1.70%-600.00K
Nuveen Quant Small Cap Equity R63.02M1.26%-26.10K
Wasatch Micro Cap2.82M1.18%2.82M

Recent Insider Transactions

DateNameRoleActivityValue
Jan 20, 2026Looker Benjamin General CounselSell$4.87K
Dec 17, 2025Koenig Sheldon L. President and CEOSell$177.20K
Dec 17, 2025Halladay Benjamin Chief Financial OfficerSell$26.90K
Dec 17, 2025Looker Benjamin General CounselSell$23.90K
Sep 17, 2025Looker Benjamin General CounselSell$17.57K

Insider Transactions Trends

DateBuySell
2026 Q1-1
2025 Q4-3
2025 Q3-5
2025 Q2-5
2025 Q1-7

ESPR Ownership FAQ

Who Owns Esperion Therapeutics?

Esperion Therapeutics shareholders are primarily institutional investors at 49.10%, followed by 0.61% insiders and 50.29% retail investors. The average institutional ownership in Esperion Therapeutics's industry, Specialty & Generic Drug Manufacturers Stocks, is 20.82%, which Esperion Therapeutics exceeds.

Who owns the most shares of Esperion Therapeutics?

Esperion Therapeutics’s largest shareholders are Blackrock funding, inc. /de (17.68M shares, 8.92%), Blackrock (13.98M shares, 8.26%), and Vanguard group (14.95M shares, 7.54%). Together, they hold 24.73% of Esperion Therapeutics’s total shares outstanding.

Does Blackrock own Esperion Therapeutics?

Yes, BlackRock owns 8.26% of Esperion Therapeutics, totaling 13.98M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 31.04M$. In the last quarter, BlackRock increased its holdings by 11.14M shares, a 392.59% change.

Who is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested?

Meditor group is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.57% of its assets in 3.79M Esperion Therapeutics shares, valued at 8.42M$.

Who is the top mutual fund holder of Esperion Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Esperion Therapeutics shares, with 5.05% of its total shares outstanding invested in 9.94M Esperion Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools